India’s COVID-19 vaccination coverage has exceeded 199.27 Cr (1,99,27,27,559) as per provisional reports till 7 am today. This has been achieved through 2,61,97,150 sessions.
COVID-19 vaccination for the age group 12-14 years was started on 16 March, 2022. So far, more than 3.76 Cr (3,76,98,593) adolescents have been administered with the first dose of COVID-19 vaccine. Similarly, the COVID-19 precaution dose administration for age group 18-59 years also started from 10th April, 2022 onwards.
The break-up of the cumulative figure as per the provisional report till 7 am today include:
Cumulative Vaccine Dose Coverage |
||
HCWs |
1st Dose |
1,04,10,027 |
2nd Dose |
1,00,77,006 |
|
Precaution Dose |
59,51,763 |
|
FLWs |
1st Dose |
1,84,26,752 |
2nd Dose |
1,76,46,995 |
|
Precaution Dose |
1,12,38,648 |
|
Age Group 12-14 years |
1st Dose |
3,76,98,593 |
2nd Dose |
2,56,32,231 |
|
Age Group 15-18 years |
1st Dose |
6,07,62,753 |
2nd Dose |
4,98,22,795 |
|
Age Group 18-44 years |
1st Dose |
55,87,50,479 |
2nd Dose |
50,50,43,015 |
|
Precaution Dose |
42,37,755 |
|
Age Group 45-59 years |
1st Dose |
20,35,44,220 |
2nd Dose |
19,43,63,195 |
|
Precaution Dose |
31,51,234 |
|
Over 60 years |
1st Dose |
12,73,41,249 |
2nd Dose |
12,14,46,533 |
|
Precaution Dose |
2,71,82,316 |
|
Precaution Dose |
5,17,61,716 |
|
Total |
1,99,27,27,559 |
India’s Active Caseload currently stands at 1,36,076. Active cases now constitute 0.31% of the country’s total Positive Cases.
Consequently, India’s recovery rate stands at 98.49%. 16,482 patients have recovered in the last 24 hours and the cumulative tally of recovered patients (since the beginning of the pandemic) is now at 4,30,28,356.
20,139 new cases were reported in the last 24 hours.
The last 24 hours saw a total of 3,94,774 COVID-19 tests being conducted. India has so far conducted over 86.81 Cr (86,81,64,348) cumulative tests.
Weekly Positivity Rate in the country currently stands at 4.37% and the Daily Positivity rate is reported to be 5.10%.
****
MV/AL
HFW/COVID States data/14 July 2022/3